Findingstech, established in 2020, is driven by a vision to "curve rescue" lives by empowering medical professionals with precise AI-driven insights derived from mechanics simulation and AI algorithm. Leveraging robust R&D capabilities in image processing and the NVIDIA MONAI framework, the company addresses the critical medical pain point of fatty liver disease through "HepatoWell.ai," which overcomes the limitations of qualitative detection by automatically quantifying liver fat density via MRI-PDFF (Proton Density Fat Fraction) signals to support new drug clinical trials and health management. Additionally, Findingstech targets the unmet demand of the surgical operation room with its "OmniSurgery" platform, a solution co-developed with medical centers to automate the detection and inventory of instruments for hospital supply centers.

Strategically, Findingstech operates as part of the Promate Group, utilizing this partnership to facilitate hardware-software integration and access global medical device leading companies. Supported by the NVIDIA Inception program, we aims to secure certification for HepatoWell.ai by 2026, initially targeting health check centers in the Asian market before expanding to the US and Europe. The potential business approach encompasses not only proprietary products but also "AI Foundry" services, fostering an ecosystem that connects clinical trial companies, pharmaceutical firms, and international equipment manufacturers. Findingstech intends to deepen its global layout and cement our position in the smart healthcare market.